CD276 and colorectal carcinoma: In this study, we explored the potential of utilizing B7 homolog 3 protein (B7-H3, also known as CD276) as a target for CAR-T cell therapy in CRC, based on our preliminary studies demonstrating a promising safety and efficacy of this treatment in other solid tumors [13].